Medtronic Launches the TruClear and HysteroLux System for diagnostic and operative hysteroscopy in India; AUB occurs in 9% to 14% of women between menarche and menopause, with India having a reported prevalence of AUB iaround 17.9%

Sample article from our Tissue & Hygiene

MUMBAI, India , November 2, 2022 (press release) –


India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc (NYSE:MDT), today announced the launch of the TruClear™ system, a mechanical hysteroscopic tissue removal system used for the safe and effective treatment of intra uterine abnormalities (IUA).

Some of the commonly seen IUA includes fibroids, polyps, retained products of conception, adhesions, malignancies, or hyperplasia.One of the symptoms of IUA is abnormal uterine bleeding (AUB). AUB refers to any vaginal bleeding that is unrelated to the normal menstrual cycle, that may manifest in the form of small amounts of spotting in between periods, or unusually heavy periods.

AUB is reported to occur in 9-14% women between menarche and menopause. The prevalence varies in each country. In India , the reported prevalence of AUB is around 17.9%.

1 Watchful waiting and removal of the uterus (called a hysterectomy) are two common treatments to AUB. Between these two extremes is hysteroscopy, a minimally invasive treatment and the gold standard for allowing surgeons to look directly into the uterus and determine if AUB is related to fibroids, polyps, retained products of conceptions, or intrauterine adhesions.2 It does not requires incisions or electric shocks, and provides patients with a quicker recovery.

“TruClear system is a new addition to our GYN and women’s health portfolio and by introducing innovations like these we’re bringing choice, control and confidence to women’s healthcare in India . The system is built to facilitate a less invasive and effective way of treating intra uterine pathologies, giving patients the choice to retain the organ and go back to routine faster. Its precision and enhanced visibility provides gynecologists much needed comfort and helps avoid complications, yielding better patient outcomes,” said Abhishek Bhargava , director, Surgical, Patient Monitoring, Respiratory Interventions & ENT, Medtronic India.

TruClear™ is a next-generation device that provides practitioners with a clear operative field and patients with gentle mechanical resection during procedure to help efficiently execute a hysteroscopy. Unlike other intrauterine abnormality treatment options that use a high-frequency electric current, the TruClear™ system uses a simple mechanical approach to remove intrauterine tissue. Therefore, there is no scarring of the uterine lining from thermal energy or electrical energy, thus providing more hope of preserving the uterus for the future.

About Medtronic

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc , headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.References
1. https://www.nhp.gov.in/disease/gynaecology-and-obstetrics/abnormal-uterine-bleeding

2. van Dongen , H. et al (2007) “Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and meta-analysis> BJOG 114(6): 664-675


 

Click here for Media Contact Details


Submit your press release

Disclaimer: This Press Release has not been vetted or endorsed by The Eastern Herald 's editorial staff.

 


The views expressed in content distributed by Newstex and its re-distributors (collectively, "Newstex Authoritative Content") are solely those of the respective author(s) and not necessarily the views of Newstex et al. It is provided as general information only on an "AS IS" basis, without warranties and conferring no rights, which should not be relied upon as professional advice. Newstex et al. make no claims, promises or guarantees regarding its accuracy or completeness, nor as to the quality of the opinions and commentary contained therein.

 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.